Better viral suppression with dolutegravir than other antiretrovirals in pregnancy, but not all guidelines recommend it
World’s largest HIV treatment programme could shift almost entirely to WHO-preferred first line regimen
Top 5 stories on HIV treatment and care in Africa from CROI 2022
Further evidence that recycling tenofovir in second-line treatment is effective
Large disparities in dolutegravir uptake persist between men and women in low and middle-income countries
First injectable therapy for HIV approved for England and Wales
Dolutegravir more likely to suppress very high viral loads than other recommended first-line drugs
Dolutegravir-based regimens result in sustained viral suppression, despite lower adherence and treatment interruptions
Most countries with the greatest burden of HIV still don’t recommend dolutegravir for all
